Dr. Jonathan Wall, Co-Founder and Interim Chief Scientific Officer at Attralus discusses the latest developments in systemic amyloidosis research, stemming from its oral and poster presentations at the XVIII International Symposium on Amyloidosis (ISA), alongside updates around its recently initiated Phase 1 trial in its lead therapeutic candidate, AT-02.
Jonathan Wall is a Professor at University of Tennessee Medical Center, Knoxville and Head of the Amyloidosis and Cancer Theranostics Program. Jonathan is an internationally known expert in the field of amyloidosis and has worked in the field of amyloidosis for over 25 years.
He has over 100 publications and more than 13 issued US patents in this field. His research work was instrumental in the development of multiple antibody-based therapeutics that have undergone clinical development by biotech companies. His lab has received over $10M in NIH grant and contract funding for work that focuses on the development and translation of novel diagnostic and therapeutic reagents for amyloidosis.